Blog Post

Pharmaceutical industry at risk from Brexit

Pharmaceuticals are a hugely important industry for the EU and the UK. The sector creates thousands of jobs, billions of euros in exports, and is Europe’s most research-intense industry. But will Brexit mean for pharma? Border delays, disruption to R&D and regulatory divergence all pose hazards.

By: Date: May 31, 2017 Topic: European Macroeconomics & Governance

Despite numerous debates about the impact of Brexit, the pharmaceutical industry seems to be less eye-catching than other sectors like the manufacturing supply chain and financial services. However, pharmaceuticals are one of the EU’s most important and fastest-growing industries, and they benefit greatly from EU integration.

Pharmaceutical in the EU has increased from €125 billion to €225 billion over the past fifteen years. Employment in the sector also grew dramatically from 535000 to 725000. The pharmaceuticals sector has also become very advantageous for the EU. Exports of pharmacy products have more than tripled over the past fifteen years, with most of these gains obtained from extra-EU transactions. Pharmaceuticals are also the third largest industry in the UK, contributing 10 percent of the UK’s GDP, with an employment of 73000 people and a trade surplus of €3.3 billion.

Table 1: The rapid growth of the European pharmaceutical industry

INDUSTRY (EFPIA total) 2000 2010 2014 2015
Production 125,316 199,400 221,088 225,000
Exports 90,935 276,357 324,452 361,500
Imports 68,841 204,824 251,427 275,000
Trade balance 22,094 71,533 73,025 86,500
R&D expenditure 17,849 27,920 30,887 31,500
Employment 534,882 670,088 723,448 725,000
R&D employment 88,397 117,035 118,052 118,000

 

Source: “The pharmaceutical industry in figures”, 2016, European federation of pharmaceutical industries and associations.

The rapid advance of the pharmaceuticals sector over the past decade can be closely associated with the integration of the EU trade chain. In 2016, around 67% of the EU’s exports of its products were intra-EU exports; 52% of the EU’s imports of its products were intra-EU imports. According to EFPIA figures, among the EU member states the UK is undoubtedly a key player, constituting 10% of the EU’s total production and employment. Moreover, the UK runs a trade deficit of €114 billion against the other EU27 countries, implying that it is a major destination for EU pharmaceutical products.

Non-tariff barriers such as the possible establishment of physical border could have negative effects on pharmaceutical trade

Fortunately, the EU has long adopted zero most-favored-nation tariffs even for international extra-EU transactions for pharmaceutical products. So the worst scenario, even in a hard Brexit where the EU and UK treat each other in the WTO multilateral framework manner, would not add a specific tariff burden on pharmaceutical trade.

However, tariffs are not the only barrier to trade. There is also a possibility that other types of non-tariff barriers could be created to hamper pharmaceutical trade. In particular, with the strengthening of immigration control, border checks might be resumed which could create delays in transferring pharmaceutical products to/from the UK. Longer lead times and increased paperwork caused by these customs bottlenecks could affect service levels and margins – especially for pharmaceutical products, which have a short shelf life. Evidence has shown that, for time-sensitive industries, every 1 hour of customs delay adds 0.8 percentage points to the ad valorem trade-cost rate and leads to 5% less trade. This means that perishable pharmaceutical products are likely to cost more for UK residents, especially in the case of emergency.

The establishment of a physical border also matters particularly for Ireland. Ireland is the only country that shares a land border with the UK. Although it is hard to say what will eventually happen in the event of Brexit until the final post-Brexit model is determined, the risk has been mounting since Theresa May’s report signaling a hard Brexit. Establishing an Irish-Irish border would mean that Irish pharmaceutical products need to go across the UK border twice before entering the rest of the EU. One solution to avoid this additional processing cost is to construct a common border for two countries, which was already the case for passengers from 16 countries such as China and India to enter the region. But that undoubtedly means additional costs for Irish pharmaceutical consumers.

Disruption of research and development (R&D) activities

One of the key characteristics of the pharmaceutical industry is its high intensity in research and development. Figure 3 shows that the pharmaceutical and biotechnology sector accounts for the highest R&D intensity in the EU, even higher than the software and computer services sector. Eurostat data also indicates that the pharmaceutical industry has the highest added-value per person employed.

Within the pharmaceutical industry, UK has long been a center for research and development (R&D) activities. In 2015, it contributed approximately 20% of the EU’s total R&D, only slightly lower than Germany and France. As Maria Demertzis and Enrico Nano highlight, these research and development activities rely on two key factors: skilled labour supply and research funding. Both factors could be at risk in the post-Brexit era. For the former, the UK has attracted a large number of skilled workers from abroad, most of which are EU citizens. For the latter, the UK gains more research funding in the current system than any other country. Therefore, Brexit could undoubtedly have a negative impact for both factors in the pharmacy industry.

 

In addition, research and development in the pharmaceutical industry rely on protections on trademarks and associated rights, which are currently covered by EU laws. The future of these activities after Brexit depends on the intellectual protection coordination arrangement between the EU and UK. The further the arrangement goes away from the current system, the more challenging the future will be.

Regulatory segmentation

The unification of the regulatory framework on product standards has eased entry barriers for pharmaceutical companies in the EU. For example, the current product standard in the European Economic Area (EEA) is authorised by the London-based European Medicines Agency (EMA), meaning that all drugs approved by EMA are automatically granted access to the UK’s market. If the UK’s post-Brexit relationship with the EU does not include a shared regulatory framework, access to the both markets would be subject to additional process. Any disruption is likely to lead to a geographic reallocation of the pharmaceutical industry. This can be detrimental for the UK but could be an opportunity for substitutive countries taking on this business.

The EMA being in London is also the reason why a number of influential pharmacy companies choose to locate their European headquarters in the UK. Ironically, even the European Medicines Agency (EMA) may find itself in an awkward situation after Brexit, because it is currently located in Canary Wharf, London. It is highly unlikely that the UK can keep the medical authority, and the long-term benefits to the UK from proximity to the EMA will also be lost.

Conclusions

The impact of Brexit on the European and British pharmaceutical industry will go far beyond the simple trade analysis based on tariffs but to more non-tariff aspects. The establishment of a physical border will cause delay in transportation not only for the UK but also Ireland. This may increase the cost of pharmaceutical products especially those with short expiration date.

Moreover, a UK outside of the EU might find it difficult to attracted skilled experts for the industry, lose research funding supported by the EU, and face barriers accessing the EU27 market. For the rest of the EU, Brexit could also cause similar additional costs on the whole, but given its larger economic size than the UK, the loss would also be smaller. For some EU countries, if they can seize the opportunity to take on UK business, or become the new location for the EMA, there is a chance to benefit despite the general loss in the EU.

Nonetheless, the best strategy to reserve benefits for both the EU and UK is still to maintain existing relationship between two parties on all the related aspects. But this seems to be an increasingly challenging task in the likely scenario of hard Brexit.


Republishing and referencing

Bruegel considers itself a public good and takes no institutional standpoint. Anyone is free to republish and/or quote this post without prior consent. Please provide a full reference, clearly stating Bruegel and the relevant author as the source, and include a prominent hyperlink to the original post.

View comments
Read article More by this author

Podcast

Podcast

Surprising priorities for Europe and China

Bruegel’s Alicia García-Herrero and Robin Niblett of Chatham House discuss a new joint report on EU-China relations. How easy was it to find common ground with Chinese partners? And what should be the priorities for economic cooperation between Europe and China?

By: The Sound of Economics Topic: Global Economics & Governance Date: September 13, 2017
Read about event More on this topic

Past Event

Past Event

EU-China economic relations: looking to 2025

This event will see the launch of a report on EU-China relations and discuss issues such as trade and investment, industrial cooperation and innovation and global governance

Speakers: Victor Chu, Ian Davis, Alicia García-Herrero, Dame Clara Furse, Tony Graziano, Anatole Kaletsky, K.C. Kwok, Lawrence J. Lau, Ina Lepel, Hanna Müller, André Sapir, Robin Niblett, György Szapáry, Jean-Claude Trichet, Zhang Yansheng, H.E. Ambassador Yang Yanyi, Liu Xiangdong, Gunnar Wiegand, Guntram B. Wolff, Huang Ping and Elena Flores Topic: Global Economics & Governance Location: Bruegel, Rue de la Charité 33, 1210 Brussels Date: September 13, 2017
Read about event

Past Event

Past Event

Bruegel Annual Meetings 2017

The Annual Meetings are Bruegel’s flagship event. They offer a mixture of large public debates and small private sessions about key issues in European and global economics. In a series of high-level discussions, Bruegel’s scholars, members and stakeholders will address the economic policy challenges facing Europe.

Speakers: Carlos Sallé Alonso, José Antonio Álvarez Álvarez, Agnès Bénassy-Quéré, Pervenche Béres, Matthias Buck, Grégory Claeys, Zsolt Darvas, Jean Luc Demarty, Maria Demertzis, Anna Ekström, Lowri Evans, Ferdinando Giugliano, Sandro Gozi, Peter Grünenfelder, Reiner Hoffmann, Levin Holle, Kate Kalutkiewicz, Steffen Kampeter, Peter Kažimír, Emmanuel Lagarrigue, Matti Maasikas, Steven Maijoor, Reza Moghadam, Nathalie Moll, James Murray, Johan Van Overtveldt, Julia Reinaud, André Sapir, Dirk Schoenmaker, Mateusz Szczurek, Marianne Thyssen, Jean-Claude Trichet, Reinhilde Veugelers, Nicolas Véron, Ida Wolden Bache, Liviu Voinea, Guntram B. Wolff and Georg Zachmann Topic: Energy & Climate, European Macroeconomics & Governance, Finance & Financial Regulation, Global Economics & Governance, Innovation & Competition Policy Location: Square - Brussels Meeting Centre Date: September 7, 2017
Read article More on this topic More by this author

Blog Post

Africa and Chinese rebalancing

What’s at stake: China and Africa have developed close economic ties over the past 20 years. The need to rebalance the China-Africa relationship was also a prominent topic in the context of the recent Kenyan elections. But if the drivers will shift relatively more towards domestic consumption, what will the impact be on Africa? We review recent contribution to this debate.

By: Silvia Merler Topic: Global Economics & Governance Date: August 28, 2017
Read article More on this topic More by this author

Blog Post

The issue of U.S. prescription drug prices

What’s at stake: Americans spend a lot on prescription drugs, more per capita than any other country by far. Individual cases of sharp price increases - like the case of the EpiPen - have recently driven attention to this issue. We report review contributions on this topic.

By: Silvia Merler Topic: Innovation & Competition Policy Date: August 24, 2017
Read about event More on this topic

Past Event

Past Event

Europe's global positioning and its trade implications for Asia

This event, taking place in Hong Kong will discuss Europe-Asia relations in the context of global developments.

Speakers: Alicia García-Herrero, Peter Mandelson, David Tweed and Guntram B. Wolff Topic: Global Economics & Governance Location: Bloomberg Hong Kong Office 25/F, Cheung Kong Center, 2 Queen's Road, Central, Hong Kong Date: July 7, 2017
Read article Download PDF More on this topic

External Publication

Review of EU-third country cooperation on policies falling within the ITRE domain in relation to Brexit

What is the possible future relationship between the EU and the UK in light of Brexit? The report provides a critical assessment of the implications of existing models of cooperation between third countries and the European Union on energy, electronic communications, research policy and small business policy.

By: J. Scott Marcus, Georgios Petropoulos, André Sapir, Simone Tagliapietra, Alessio Terzi, Reinhilde Veugelers and Georg Zachmann Topic: European Macroeconomics & Governance Date: July 5, 2017
Read article More on this topic More by this author

Podcast

Podcast

Global trade and Europe

Multilateral trade has generated a huge amount of wealth, and lifted many around the world out of poverty. But there is also growing awareness that globalisation is creating “losers”, and this risks feeding a backlash against multilateral trade. We explore the benefits and risks of multilateral trade, and ask how Europe should behave in a shifting context

By: The Sound of Economics Topic: Global Economics & Governance Date: June 30, 2017
Read article More on this topic

Blog Post

Can EU actors keep using common law after Brexit?

English common law is the choice of law for financial contracts, even for parties in EU members with civil law systems. This creates a lucrative legal sector in the UK, but Brexit could make UK court decisions difficult to enforce in the EU. Parties will be able to continue using English common law after Brexit, but how will these contracts be enforced? Some continental courts are preparing to make judicial decisions on common law cases in the English language.

By: Uuriintuya Batsaikhan and Dirk Schoenmaker Topic: European Macroeconomics & Governance Date: June 22, 2017
Read article More by this author

Parliamentary Testimony

House of Commons

Exiting the European Union Committee

On 19 April 2017 Zsolt Darvas appeared as a witness at the Exiting the European Union Committee, the House of Commons, United Kingdom.

By: Zsolt Darvas Topic: European Macroeconomics & Governance, House of Commons, Testimonies Date: June 20, 2017
Read article More on this topic More by this author

Blog Post

Brexit and the future of the Irish border

The future of the Irish land border has been thrown into uncertainty by Brexit. The UK's confirmation that it will leave the EU's single market and customs union implies that customs checks will be needed. However, there is little desire for hard controls from any of the parties involved. This is especially true for Theresa May's potential partner, the DUP. Creative solutions are needed to reach a solution.

By: Filippo Biondi Topic: European Macroeconomics & Governance Date: June 19, 2017
Read about event More on this topic

Past Event

Past Event

Substance requirements for financial firms moving out from the UK

In the run-up to Brexit, UK-based financial firms are considering how to organize their operations across the future divide between the UK and EU27. This event will discuss the regulatory requirements on how self-sustaining the operations in the EU should be, and implications for the single market and third countries.

Speakers: Gerry Cross, Simon Gleeson and Nicolas Véron Topic: Finance & Financial Regulation Location: Bruegel, Rue de la Charité 33, 1210 Brussels Date: June 2, 2017
Load more posts